Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vardenafil - Respira Therapeutics

Next Previous
Drug Profile

Vardenafil - Respira Therapeutics

Alternative Names: RT-234; RT234 AOS™ DPI; RT234-PAH

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Respira Therapeutics
  • Developer Respira Therapeutics; United Therapeutics Corporation
  • Class Antifibrotics; Antihypertensives; Bronchodilators; Erectile dysfunction therapies; Imidazoles; Piperazines; Small molecules; Sulfones; Triazines
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • No development reported Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Pulmonary hypertension

Most Recent Events

  • 25 Sep 2025 Efficacy and adverse events data from two phase II trials in Pulmonary arterial hypertension released by Gossamer Bio
  • 17 May 2025 Adverse events and efficacy data from the phase II CL202 trial for Pulmonary arterial hypertension presented at the 121st International Conference of the American Thoracic Society (ATS-2025)
  • 07 Jan 2025 Respira Therapeutics completes a phase-II trial in Pulmonary arterial hypertension (Treatment-experienced) in USA (Inhalation) (NCT04266197)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top